Update in palliative management of hormone refractory cancer of prostate
- PMID: 19675762
- PMCID: PMC2721495
- DOI: 10.4103/0970-1591.30266
Update in palliative management of hormone refractory cancer of prostate
Abstract
Hormone refractory prostate cancer (HRPC) is an incurable disease and as in the pressure sensitive adhesive era the median survival of patients is increasing, these men increasingly develop symptomatic problems as a result of advanced local and or metastatic disease during their progression to death. Recently, it has been shown that it is possible to improve survival in this group of patients with use of chemotherapy which reinforces the need of better options in palliative care. We discus the various clinical problems (Part I) and treatment options of palliative care (Part II) and try to formulate an action plan in this review.
Keywords: Cancer prostate; hormone refractory; hormone refractory cancer of prostate; palliative care; prostate.
Conflict of interest statement
Similar articles
-
Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.Int J Immunopathol Pharmacol. 2006 Jan-Mar;19(1):11-34. Int J Immunopathol Pharmacol. 2006. PMID: 16569343 Review.
-
Second-line chemotherapy for advanced hormone-refractory prostate cancer.Clin Adv Hematol Oncol. 2008 Feb;6(2):118-22, 127-32. Clin Adv Hematol Oncol. 2008. PMID: 18347563 Review.
-
Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?Cancer. 2007 Feb 1;109(3):477-86. doi: 10.1002/cncr.22439. Cancer. 2007. PMID: 17186531 Review.
-
Treatment options in hormone-refractory metastatic prostate carcinoma.Tumori. 2004 Nov-Dec;90(6):535-46. doi: 10.1177/030089160409000601. Tumori. 2004. PMID: 15762353 Review.
-
Management of the spectrum of hormone refractory prostate cancer.Eur Urol. 2006 Sep;50(3):428-38; discussion 438-9. doi: 10.1016/j.eururo.2006.05.017. Epub 2006 Jun 2. Eur Urol. 2006. PMID: 16797118 Review.
Cited by
-
Management of bleeding in palliative care patients in the general internal medicine ward: a systematic review.Ann Med Surg (Lond). 2019 Dec 18;50:14-23. doi: 10.1016/j.amsu.2019.12.002. eCollection 2020 Feb. Ann Med Surg (Lond). 2019. PMID: 31908774 Free PMC article. Review.
References
-
- Huggins C, Hodges C. Studies on prostatic cancer: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–9. - PubMed
-
- Gleave ME, Small EJ. Androgen deprivation therapy for prostate cancer. In: Carroll PR, Nelson WG, editors. Report to the Nation on Prostate Cancer. Medscape: Elmwood Park; 2004. pp. 27–36.
-
- Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232–7. - PubMed
-
- Oefelein MG, Agrawal PK, Resnick M. Survival of the patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol. 2004;171:1525–8. - PubMed
-
- Newling D, Fossa SD, Andersson L, Abrahamsson PA, Aso Y, Eisenberger MA, et al. Assessment of hormone refractory prostate cancer. Urology. 1997;49:46–53. - PubMed
